GDC-0927
GDC-0927 (SRN-927) is a selective oral estrogen receptor degrader (SERD) in a phase I clinical trial for the treatment of postmenopausal women with locally advanced or metastatic estrogen receptor positive breast cancer. Study shows well tolerability and clinical effect.
| Supplier | BOC Sciences |
|---|---|
| Product # | 1642297-01-5 |
| Pricing | Inquire |
| Cas | 1642297-01-5 |
| Molecular Weight | 461.52 |
| Molecular Formula | C28H28FNO4 |
| Canonical SMILES | CC1=C(C(OC2=C1C=C(C=C2)O)C3=CC=C(C=C3)OCCN4CC(C4)CF)C5=CC(=CC=C5)O |